Document Detail


Enteric-coated mycophenolate sodium as a corticosteroid-sparing agent for the treatment of autoimmune scleritis.
MedLine Citation:
PMID:  21099416     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To evaluate enteric-coated mycophenolate sodium (EC-MPS) as a corticosteroid-sparing agent in the treatment of autoimmune scleritis.
METHODS: A retrospective, interventional, noncomparative review of EC-MPS use in patients with autoimmune scleritis.
RESULTS: Seven eyes of 5 patients (all female; median age: 47 years, range: 20-55 years) with inflammatory scleral disease were treated with EC-MPS. The mean follow-up duration was 16.4 months (range, 12-20 months). EC-MPS was started at 360 mg twice daily. The mean time to treatment success was 1.6 months (range, 1-3 months). The mean prednisolone dosage at the onset of EC-MPS was 24 mg daily (range, 15-30 mg), and this was reduced to 6.5 mg daily (range, 0-10 mg) as inflammation control was achieved. No severe adverse events except for 1 patient with transient knee pain were reported; the incidence of adverse events after using EC-MPS was 1/6.83 person-years. There was no recurrence of scleral inflammation during the follow-up period.
CONCLUSIONS: EC-MPS can be used as a corticosteroid-sparing agent to safely suppress inflammatory autoimmune scleritis.
Authors:
Yih-Shiou Hwang; Hung-Chi Jesse Chen; Kuan-Jen Chen; Chi-Chun Lai; Ling Yeung; Ko-Jen Yang; Ken-Kuo Lin; Ching-Hsi Hsiao
Related Documents :
356916 - Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo.
1792646 - Pneumocystis carinii pneumonia as a complication of methotrexate treatment of asthma.
11150966 - Intravenous immunoglobulin therapy for guillain-barré syndrome with igg anti-gm1 antib...
12197896 - Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy. long-term ...
23261096 - Adenoma detection rate is necessary but insufficient for distinguishing high versus low...
17390196 - Palliative stenting for late malignant gastric outlet obstruction.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Cornea     Volume:  30     ISSN:  1536-4798     ISO Abbreviation:  Cornea     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-02-10     Completed Date:  2011-05-05     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  8216186     Medline TA:  Cornea     Country:  United States    
Other Details:
Languages:  eng     Pagination:  260-4     Citation Subset:  IM    
Affiliation:
Department of Ophthalmology, Chang Gung Memorial Hospital and Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan, ROC.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anti-Inflammatory Agents, Non-Steroidal / adverse effects,  therapeutic use
Autoimmune Diseases / drug therapy*
Female
Follow-Up Studies
Glucocorticoids / administration & dosage*
Humans
Immunosuppressive Agents / adverse effects,  therapeutic use*
Middle Aged
Mycophenolic Acid / adverse effects,  analogs & derivatives*,  therapeutic use
Prednisolone / administration & dosage*
Retrospective Studies
Scleritis / drug therapy*
Tablets, Enteric-Coated
Treatment Outcome
Young Adult
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Glucocorticoids; 0/Immunosuppressive Agents; 0/Tablets, Enteric-Coated; 24280-93-1/Mycophenolic Acid; 50-24-8/Prednisolone; 9242ECW6R0/mycophenolate mofetil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Tolerance and biocompatibility of micronized black pigment for keratopigmentation simulated pupil re...
Next Document:  A Multicenter, Double-Blind, Parallel Group, Placebo-Controlled Clinical Study to Examine the Safety...